types of glp 1 Frontiers When it comes to the

Enter microdosing a strategy where people take smaller-than-standard doses of GLP-1s in hopes of reaping the benefits with fewer side effects

Finally, patient-reported experiences should be placed at the center of developing future treatment models

Efficacy and safety of omarigliptin, a novel once-weekly dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus: a systematic review and meta-analysis

doi: 10.1007/s10557-025-07670-9, 56

Common initial effects During the first one to two weeks, some users report: Increased gas and flatulence Mild bloating Slight changes in stool consistency Occasional mild nausea These symptoms are typical of any probiotic introduction and reflect the microbiome adjusting to new bacterial populations